Prothena Corporation plc Ordinary Shares

PRTANASDAQ • USD
7.91 USD
↘ 0.26 (3.12%)🟢LIVE (AS OF 01:42 PM EST)
🟢Market: OPEN

PRTA is currently priced at $7.91. Technical and fundamental signals converge bearish — technicals rate "Strong Sell" while fundamentals read "Sell". Notable factors include a robust Altman Z-Score, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. Valuation metrics place PRTA at a fair price relative to peers.

Technical & fundamental data as of Nov 13, 2026.

Open?$8.13
High?$8.43
Low?$7.86
Prev. Close?$8.16
Volume?99.9K
Avg. Volume?507.7K
VWAP?$7.97
Rel. Volume?0.20x
Bid / Ask
Bid?$7.90 × 100
Ask?$7.92 × 200
Spread?$0.02
Midpoint?$7.91
Valuation & Ratios
Market Cap?419.0M
Shares Out?51.3M
Float?41.1M
Float %?78.5%
P/E Ratio?N/A
P/B Ratio?1.56
EPS?-$0.47
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.
Employees
67
Market Cap
419.0M
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2012-12-18
Address
77 SIR JOHN ROGERSON'S QUAY, BLOCK C
DUBLIN 2, L2 D02 VK60
Phone: 011-353-1-236-2500
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
23
Z-Score?
100
Momentum?
17
Short Sent.?
39
Piotroski F-Score?3/9Weak
Altman Z-Score?11.36Safe
Confidence?51%Low
Full Fundamental Analysis →
Short InterestVery High
Short % of Float?19.26%High
Short Interest?7.9M
Days to Cover?15.7
Free Float41.1M
Avg Daily Volume504.2K
Settlement Date2026-10-30
Financial Health
Current Ratio?23.95Strong
Quick Ratio?23.95Strong
Cash Ratio?23.73Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
83/100
P/E?
N/A▾
P/B?
Peers
100
S&P
86
1.56CHEAP▾
P/S?
Peers
100
S&P
13
7.95HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-3.9CHEAP▾
EV/Sales?
Peers
100
S&P
63
2.80CHEAP▾
Returns & Efficiency
ROE?
S&P
10
-8.9%WEAK▾
ROA?
S&P
3
-8.5%WEAK▾
Cash Flow & Enterprise
FCF?$-32172000
Enterprise Value?$147.6M
Fundamentals ratios updated end of day